Net sales fell 28% year-over-year in H1 2025, but EBITDA turned positive and net loss narrowed. Strategic restructuring, cost reductions, and a major ambulance order support a more stable outlook, despite weak hearse demand and challenging market conditions.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.